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bjectives The aim of this study was to clarify whether pioglitazone suppresses in-stent neointimal
roliferation and reduces restenosis and target lesion revascularization (TLR) after percutaneous cor-
nary intervention (PCI).
ackground Previous single-center studies have demonstrated the anti-restenotic effect of a peroxi-
ome proliferator-activated receptor gamma agonist, pioglitazone, after PCI.
ethods A total of 97 patients with type 2 diabetes mellitus (T2DM) undergoing PCI (bare-metal stents
nly) were enrolled. After PCI, patients were randomly assigned to either the pioglitazone group (n 
8) or the control group (n  49). Angiographical and intravascular ultrasound (IVUS) imaging were per-
ormed at baseline and repeated at 6-month follow-up. Primary end points included angiographical re-
tenosis and TLR at 6 months follow-up. Secondary end point was in-stent neointimal volume by IVUS.
esults Baseline glucose level and glycosylated hemoglobin (HbA1c) level were similar between the
ioglitazone group and the control group. Angiographical restenosis rate was 17% in the pioglitazone
roup and 35% in control group (p  0.06). The TLR was signiﬁcantly lower in pioglitazone group than
n control group (12.5% vs. 29.8%, p  0.04). By IVUS (n  56), in-stent neointimal volume at 6 months
howed a trend toward smaller in the pioglitazone group than in the control group (48.0  30.2 mm3
s. 62.7  29.0 mm3, p  0.07). Neointimal index (neointimal volume/stent volume  100) was signiﬁ-
antly smaller in the pioglitazone group than in the control group (31.1  14.3% vs. 40.5  12.9%,
 0.01).
onclusions Pioglitazone treatment might suppress in-stent neointimal proliferation and reduce
ncidence of TLR after PCI in patients with T2DM. (J Am Coll Cardiol Intv 2009;2:524–31)
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525ince the introduction of the drug-eluting stent (DES),
ncidence of in-stent restenosis (ISR) decreased dramatically
nd consistently compared with bare-metal stent (BMS)
1,2). Despite the aggressive use of DES, ISR still occurs in
ome high-risk patients.
See page 532
Previous studies have demonstrated that diabetes is 1 of
he strongest clinical predictors of ISR after DES (3–6) as
ell as BMS (7,8). More important, diabetes is also an
ndependent predictor of stent thrombosis. Recent concerns
bout very late stent thrombosis have raised questions about
he unselected use of DES to treat patients with high
ikelihood of recurrent luminal narrowing after percutane-
us coronary intervention (PCI) (9,10).
Pioglitazone, 1 of the thiazolidinediones (TZDs) used to
reat type 2 diabetes mellitus (T2DM), has been shown to
educe neointimal proliferation after BMS placement (11).
lthough single-center studies have shown possible inhibitory
ffects of in-stent neointimal proliferation by TZDs (11–16),
he impact of neointimal inhibition on clinical end points has
ot been confirmed by any multicenter study (11,17).
Accordingly, we hypothesized that pioglitazone treatment
ight suppress in-stent neointimal proliferation and decrease
ncidence of restenosis and target lesion revascularization
TLR).
ethods
tudy design. The POPPS study (prevention of in-stent neo-
ntimal proliferation by pioglitazone study) is a prospective,
ulticenter, open-label, randomized, controlled study to in-
estigate efficacy of pioglitazone on neointimal suppression
fter PCI in patients with T2DM and symptomatic ischemic
eart disease.
Between July 2003 and March 2006, patients with both
2DM and symptomatic ischemic heart disease (stable
ngina pectoris, unstable angina pectoris/non–ST-segment
levation myocardial infarction (MI), or ST-segment eleva-
ion MI) who underwent PCI were enrolled in this study.
atients were diagnosed as T2DM if: 1) fasting plasma
lucose level was126 mg/dl; 2) glucose level 2 h after 75-g
ral glucose tolerance test was 200 mg/dl; or 3) patient
ad a known medical history of T2DM. Exclusion criteria
ere presence of end stage disease, cardiogenic shock or
ongestive heart failure at the time of PCI, contraindication
o antiplatelet therapy, patients who were already taking
ioglitazone, patients with gastrointestinal bleeding or tran-
ient ischemic attack, ineligible for coronary artery bypass
rafting, and ineligible for PCI.
After PCI, patients were randomly assigned to either the
ioglitazone (30 mg daily) or the control group. On average,
ioglitazone was started 3 days after the PCI procedure. Sny antidiabetic medications other than TZDs were al-
owed in either the pioglitazone or the control group to
ptimally control diabetic status.
ngiographic and intravascular ultrasound procedure. Cor-
nary angiography was performed following the standard
emoral or radial approach. All patients received intravenous
eparin (100 U/kg) before the procedures. After intracoro-
ary nitroglycerin (200 g) or isosorbide dinitrate (2 mg)
dministration, diagnostic angiography was performed. In-
ravascular ultrasound (IVUS) imaging was performed at
aseline and repeated after PCI. Because DES was not
vailable at the time of the initial enrolment, DES was not
llowed throughout the entire study period. Intravascular
ltrasound imaging was performed with automated pullback
evice at a rate of 0.5 mm/s.
fter diagnostic IVUS examina-
ion, PCI was performed in a
sual manner to achieve diame-
er stenosis of 25% with
hrombolysis In Myocardial In-
arction flow grade 3. After PCI,
atients were maintained on a
egimen of aspirin (81 to 100 mg
aily) plus ticlopidine (200 mg
aily) for at least 4 weeks.
ilostazole (200 mg daily) was
lternatively used, if ticlopidine
as not tolerable. In this study
eriod, either clopidogrel or gly-
oprotein IIb/IIIa inhibitors
ere not available.
uantitative coronary angiog-
aphy. All angiography was an-
lyzed at an independent core
aboratory (Cardiovascular Core
nalysis Laboratory, Stanford
niversity, Stanford, California)
y an analyst (K.W.) blinded to
he clinical and IVUS informa-
ion. Angiographic frames were
igitized and analyzed with an automated edge-detection
lgorithm (Quant32, Sanders Data Systems, Palo Alto,
alifornia). The minimal lumen diameter (MLD) inside
nd outside the stent and reference diameter were used to
alculate the percent diameter stenosis before and after PCI.
ltrasound imaging protocol. A commercially available sys-
em (CVIS/Boston Scientific Corporation, San Jose, Cali-
ornia) was used for IVUS examination. The system con-
isted of a single-element 40-MHz transducer mounted on
he tip of a flexible shaft and rotating at 1,800 rpm within
2.6-F rapid exchange/common distal lumen imaging
heath. Ultrasound images were recorded on half-inch,
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CSA  cross-sectional area
DES  drug-eluting stent(s)
EEM  external elastic
membrane
HbA1c  glycosylated
hemoglobin
ISR  in-stent restenosis
IVUS  intravascular
ultrasound
MI  myocardial infarction
MLD  minimal lumen
diameter
PCI  percutaneous
coronary intervention
PM  plaque plus media
TLR  target lesion
revascularization
TZDs  thiazolidinediones
T2DM  type 2 diabetes
mellitusuper-VHS videotape for offline quantitative analysis.
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526uantitative and qualitative coronary ultrasound analysis.
ll ultrasound images were reviewed and evaluated for both
ualitative and quantitative parameters at an independent
ore laboratory (Cardiovascular Core Analysis Laboratory,
tanford University) by an analyst (M.Y.). The images were
igitized to perform morphometric analysis with commer-
ially available planimetry software (echoPlaque, Indec
edical Systems, Santa Clara, California). Lumen and
tent cross-sectional areas (CSA) were measured through-
ut the stented segment at 1.0-mm increments. Neointimal
SA was then calculated as a difference between stent and
umen CSA. Lumen, stent, and neointimal volume were
alculated with Simpson’s method. Neointimal index was
alculated as: neointimal volume/stent volume  100 (18).
umen and external elastic membrane (EEM) CSA were
easured at 1.0-mm increments for 5.0 mm from both
roximal and distal stent edges in a subset of patients.
laque plus media (PM) CSA was calculated as EEM
inus lumen CSA. The EEM, lumen, and PM volume
ere calculated with Simpson’s method. The EEM, lumen,
nd PM volume index were calculated as volumes divided
y 5 mm.
linical follow-up. Thirty-day clinical events, including
eath, MI, TLR, and heart failure, were documented by
hart review.
Long-term clinical events, including death, MI, TLR,
eart failure requiring hospital stay, and peripheral edema
equiring diuretics, were also obtained both at 6 and 12
onths after the index PCI procedure. Target lesion revas-
ularization was defined as clinically driven repeat revascu-
arization (either repeat PCI or coronary artery bypass
rafting) of the initially treated target lesion, including
tented segments and peri-stent segments 5 mm from both
roximal and distal stent edges.
tudy end points. Primary end points of this study were
ngiographical restenosis rate and TLR rate at 6 months.
Secondary end point was in-stent neointimal volume or
eointimal index by IVUS.
tatistical analysis. With a 2-sided test for differences in
ndependent binomial proportions with an alpha level of
.05, we calculated that 95 patients would have to undergo
andomization for the study to have 80% power to detect a
eduction in the primary end point of ISR from an antici-
ated 43% in the control group to 17% in the pioglitazone
roup. Quantitative data were presented as a mean  SD
r median with interquartile range, depending on the
istribution of the variable, and qualitative data were
resented as frequencies. Continuous variables were com-
ared with paired and unpaired t tests. If normality failed,
ilcoxon test and Mann-Whitney test were used. Binary
ariables were examined by use of Fisher exact and chi-
quare tests. All p values are 2-sided and not adjusted for
ultiplicity. All statistical analyses were performed with thetatview version 5.0 (SAS Institute, Cary, North Carolina).esults
linical characteristics. A total of 97 patients were enrolled
n this study. There were 82 men and 15 women, with a
ean age of 63 9 years. Among all patients, 26 (27%) had
table angina pectoris, 22 (23%) had unstable angina
ectoris/non-ST-segment elevation MI, and 49 (51%) had
T-segment elevation MI.
After randomization, 48 patients were assigned to the
ioglitazone group and 49 patients to the control group.
aseline clinical characteristics were well-matched, with no
ignificant differences in the frequency of the clinical risk
actors (Table 1). Lesion characteristics were also well-
atched between the 2 groups (Table 2).
rocedure characteristics. There were no significant differ-
nces in interventional procedures (Table 2). Mean stent
ize was 3.5 mm in both groups, and maximal balloon
nflation pressure was 13.5 atm in the pioglitazone group
ersus 13.9 atm in the control group (p  NS).
aboratory data and medications. Laboratory data at base-
ine and at follow-up are summarized in Table 3. Fasting
lucose and glycosylated hemoglobin (HbA1c) levels were
imilar between the groups at baseline and at 6-month
ollow-up. During 6-month follow-up, fasting glucose and
bA1c level significantly decreased in both groups. Simi-
arly, low-density lipoprotein cholesterol, high-density li-
oprotein cholesterol, and triglyceride level did not differ
etween the groups either at baseline or at follow-up.
-reactive protein did not differ either at baseline or at
ollow-up between the 2 groups. Serial change (Delta) in
ach laboratory data was calculated as each value at
ollow-up minus that at baseline. Delta fasting glucose,
elta HbA1c, Delta total cholesterol, Delta low-density
ipoprotein cholesterol, Delta high-density lipoprotein cho-
esterol, Delta triglyceride, and Delta C-reactive protein
ere similar between the 2 groups (all p  NS).
Medications other than pioglitazone are summarized in
able 4. There were no significant differences in medica-
Table 1. Clinical Characteristics
Pioglitazone
(n  48)
Control
(n  49) p Value
Age (yrs), mean  SD 64.0  8.8 62.4  9.8 NS
Male, n (%) 40 (83) 42 (86) NS
Risk factors, n (%)
Hypertension 32 (67) 26 (53) NS
Diabetes 48 (100) 49 (100) —
Dyslipidemia 28 (58) 29 (59) NS
Smoking 24 (50) 26 (53) NS
Family history 6 (13) 6 (12) NS
History of MI, n (%) 11 (23) 9 (18) NS
CABG, n (%) 1 (2) 3 (6) NSCABG coronary artery bypass grafting; MImyocardial infarction.
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527ions. Among all patients, statin was prescribed in 59% and
ngiotensin-converting enzyme inhibitors/angiotensin II
eceptor blockers were prescribed in 59%; insulin was used
n 7%, sulfonylurea in 43%, alfa-glucosidase inhibitors in
3%, and metformin in 9%.
uantitative coronary angiography results. Coronary an-
iography was repeated in 86 patients (46 in the pioglita-
one group, 40 in the control group) at 6 months. Quanti-
ative coronary angiography results are shown in Table 5.
here were no significant differences in pre-intervention
eference vessel size, MLD, pre-intervention percent diam-
ter stenosis, and lesion length. Similarly, MLD and per-
ent diameter stenosis after intervention did not differ
etween the 2 groups.
At 6-month follow-up, MLD showed a trend toward
arger in the pioglitazone group than in the control group
p  0.08) (Table 5). Percent diameter stenosis was signif-
cantly lower in the pioglitazone group. Late loss was
ignificantly smaller in the pioglitazone group. The fre-
uency of binary restenosis was 17% in the pioglitazone
roup and 35% in the control group (p  0.06) (Fig. 1).
Table 2. Procedural Characteristics
Pioglitazone
(n  48)
Control
(n  49) p Value
Clinical presentation
SAP/UAP/AMI 14/10/24 12/12/25 NS
Target lesion
LAD/LCX/RCA 17/8/23 22/14/13 NS
Lesion type
A or B1/B2 or C 22/26 22/27 NS
Stent size, mm 3.5 0.4 3.5 0.5 NS
Stent length, mm 17.0 4.5 17.5 5.5 NS
Final balloon size, mm 3.5 0.4 3.5 0.5 NS
Maximal balloon inﬂation pressure,
atm
13.5 2.9 13.9 3.1 NS
AMI acute myocardial infarction; LAD left anterior descending artery; LCX left circumflex;
RCA right coronary artery; SAP stable angina pectoris; UAP unstable angina pectoris.
Table 3. Laboratory Data
Pioglitazone (n  48)
Baseline Follow
Fasting glucose, mg/dl 170 73 132
HbA1c, % 7.5 1.8 6.8
Total cholesterol, mg/dl 197 48 188
LDL cholesterol, mg/dl 119 39 111
HDL cholesterol, mg/dl 44 15 49
Triglyceride, median (IQR), mg/dl 139.5 (90.0–209.0) 129.5 (99
CRP, median (IQR), mg/l 3.0 (1.2–4.0) 1.1 (0.6
*p 0.05 versus baseline.CRP C-reactive protein; HbA1c glycosylated hemoglobin; HDL high-density lipoprotein; IQR inVUS results. IVUS imaging was performed in 56 patients
28 in each group) at 6 months. In-stent neointimal volume
t 6-month follow-up was 48.0  30.2 mm3 in the
ioglitazone group and 62.7  29.0 mm3 in the control
roup (p  0.07). Neointimal index was significantly
maller in the pioglitazone group than in the control group
31.1  14.3% vs. 40.5  12.9%, p  0.01) (Fig. 1).
Stent edge measurements were available in 42 edges from
9 patients (14 in the pioglitazone group and 15 in the
ontrol group). Serial changes in EEM, PM, and lumen
olume index did not differ between the pioglitazone group
nd the control group (Fig. 2).
0-day and long-term clinical follow-up. The 30-day clinical
vents including death (0% vs. 0%), MI (2.0% vs. 2.0%), and
LR (2.0% vs. 0%) were similar between the pioglitazone
roup and the control group. Congestive heart failure was
ot documented during the initial hospital stay.
Control (n  49)
p ValueBaseline Follow-Up
162 63 145 55* NS
7.0 1.5 6.5 1.2* NS
202 39 184 39* NS
124 30 107 31* NS
44 10 48 18 NS
0) 145.0 (102.0–209.0) 123.5 (91.0–170.0) NS
2.0 (1.0–7.5) 1.3 (0.48–3.3) NS
Table 4. Medications
Pioglitazone
(n  48)
Control
(n  49) p Value
Aspirin 48 (100) 49 (100) NS
Ticlopidine 40 (83) 40 (82) NS
Cilostazole 8 (17) 9 (18) NS
Nitrates 16 (33) 17 (35) NS
Nicorandil 17 (35) 15 (31) NS
Calcium antagonists 12 (25) 11 (22) NS
Beta-blockers 18 (38) 19 (39) NS
ACEI 18 (38) 11 (22) NS
ARB 13 (27) 15 (31) NS
Diuretics 5 (10) 10 (20) NS
Statin 31 (65) 26 (53) NS
Insulin 2 (4) 5 (10) NS
Sulfonylurea 20 (42) 22 (45) NS
Alfa-GI 8 (17) 14 (29) NS
Metformin 3 (6) 6 (12) NS
Values are n (%).
ACEI  angiotensin converting enzyme inhibitors; ARB  angiotensin II receptor blockers;
Alfa-GI alpha-glucosidase inhibitors.-Up
45*
1.0*
27
28
12*
.0–172.
–3.9)terquartile range; LDL low-density lipoprotein.
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528Long-term clinical follow-up at 6 months are summa-
ized in Table 6. Incidence of death and MI did not differ
etween the 2 groups. In contrast, TLR (all repeat PCI) rate
as significantly lower in the pioglitazone group than in the
Table 5. Quantitative Coronary Angiography
Pioglitazone
(n  46)
Control
(n  40) p Value
Before
Reference diameter, mm 2.55 0.48 2.47 0.56 NS
MLD, mm 0.65 0.56 0.66 0.52 NS
Diameter stenosis, % 75.2 20.4 73.3 20.8 NS
Lesion length, mm 10.5 5.0 10.4 5.5 NS
After
MLD, mm 2.54 0.43 2.54 0.47 NS
Diameter stenosis, % 6.8 13.6 6.1 11.2 NS
Follow-up
MLD, mm 1.83 0.56 1.57 0.65 0.08
Diameter stenosis, % 26.2 16.6 36.0 23.1 0.03
Binary restenosis rate, % 17.4 35.0 0.06
Late loss, mm 0.69 0.52 1.00 0.49 0.02
MLDminimal lumen diameter.
Figure 1. Primary and Secondary End Points
(A) Angiographic restenosis at 6 months after percutaneous coronary inter-
vention with and without pioglitazone. Restenosis rate showed a trend
toward lower in the pioglitazone group than in the control group. (B) Tar-
get lesion revascularization (TLR) at 6 months. The TLR rate was signiﬁ-
cantly lower in the pioglitazone group than in the control group. (C)
In-stent neointimal volume and (D) neointimal volume index at 6 months.
Neointimal volume index was signiﬁcantly lower in the pioglitazone group
than in the control group. Open bars represents pioglitazone group; solid
bars represents control group.ontrol group (12.5% vs. 29.8%, p  0.04) (Fig. 1). As a
esult, the major adverse cardiac event (death, MI, or TLR)
ate was significantly lower in the pioglitazone group than
he control group (13% vs. 31%, p  0.02).
Congestive heart failure requiring a hospital stay was
imilarly observed in both groups (2% vs. 4%, p  NS).
eripheral edema requiring diuretics tended to be more
requently observed in the pioglitazone group than in the
ontrol group (4% vs. 0%, p  NS), although the difference
id not reach statistical significance.
At 12-month follow-up, death (2% vs. 6%, p 0.29) and
I (2% vs. 2%, p  0.99) were similar between the 2
roups. The TLR (12.5% vs. 31.9%, p  0.02) as well as
ajor adverse cardiac events (14.6% vs. 36.2%, p  0.01)
ere significantly lower in the pioglitazone group than the
ontrol group.
iscussion
he main findings of this study were as follows: 1) piogli-
azone reduced incidence of angiographical restenosis and
Figure 2. Serial Changes in Intravascular Ultrasound Parameters at Stent
Edges During 6-Month Follow-Up
∆EEM  serial changes in external elastic membrane volume index; ∆PM
 serial changes in plaque plus media volume index; ∆lumen  serial
changes in lumen volume index.
Table 6. Clinical Follow-Up at 6 Months
Pioglitazone
(n  48)
Control
(n  47) p Value
Death 0 (0) 0 (0) NS
MI 1 (2) 1 (2) NS
TLR 6 (13) 14 (29.8) 0.04
MACE 6 (13) 15 (32) 0.02
Congestive heart failure 1 (2) 2 (4) NS
Peripheral edema 2 (4) 0 (0) NS
Hypoglycemia 0 (0) 0 (0) NS
Values are n (%).
MACEmajor adverse cardiac events; MImyocardial infarction; TLR target lesion revas-cularization.
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529LR after PCI without increasing incidence of death, MI,
ongestive heart failure, or peripheral edema; and 2) IVUS
nvestigation revealed that pioglitazone significantly sup-
resses in-stent neointimal proliferation.
Our present results were in concordance with previous
ingle-center studies (11–15,19). Takagi et al. (12) first
eported that troglitazone significantly reduced ISR. Sub-
equently, Takagi et al. (11) demonstrated that pioglitazone
imilarly reduced in-stent neointimal volume by IVUS and
ossibly decreased incidence of ISR and TLR. However,
he impact of pioglitazone on clinical end points did not
each statistical significance, possibly because of small sam-
le size (11).
Efficacy of pioglitazone on neointimal suppression was
lso evaluated in patients without diabetes (20,21). Marx et
l. (20) demonstrated similar neointimal inhibitory effect
mong a non-diabetic population. Similarly, Katayama et al.
21) demonstrated neointimal suppression of pioglitazone in
on-diabetic patients with metabolic syndrome.
Although efficacy of TZDs on neointimal proliferation
as been reported consistently and repeatedly, these data
ere limited by the single-center study design and a lack of
n independent core laboratory for image analysis. There-
ore, our present study was designed and conducted to
vercome these limitations and clearly confirmed that pio-
litazone significantly suppresses in-stent neointimal prolif-
ration and, as a result, decreased the rate of in-stent
estenosis and lowered the chance of TLR. Because glyce-
ic control as well as lipid prolife did not differ between
hose treated with and without pioglitazone, it is unlikely
hat glycemic control itself affected neointimal suppression.
herefore, the pleiotropic effect of TZDs might be associ-
ted with neointimal suppression. There are several possible
echanisms by which pioglitazone affects in-stent neointi-
al proliferation. First, it has been reported that TZDs
ave an inhibitory effect on smooth muscle migration and
roliferation in animal models (22–25). This might be
elated to less neointimal proliferation after vascular injury
ade by metallic stent implantation. Second, Aizawa et al.
26) reported that pioglitazone might enhance apoptosis in
ascular smooth muscle cells. Third, anti-inflammatory
ffects of TZDs have been reported, possibly affecting the
estenotic process (27–29). Although C-reactive protein
evel did not significantly change over time after pioglita-
one administration in this study, a small but significant
mpact of TZDs on local inflammation might play a role. In
act, results from a recently published larger-scale random-
zed study demonstrated that pioglitazone more favorably
ffected C-reactive protein than glimepiride (30). Fourth,
n antithrombotic effect of pioglitazone has been reported
31–33). Therefore, this might be related to suppression of
n early vascular response (i.e., fibrin formation) after stent
mplantation that leads to subsequent neointimal prolifera-
ion and restenosis (34). Finally, pioglitazone has been feported to decrease fasting insulin level, because of its
nsulin sensitizing effect (30). Hyperinsulinemia is a known
romoter of atherosclerosis progression and neointimal
roliferation after intervention (18). Although fasting insu-
in level has not been evaluated, it is possible that decreased
asting insulin affected the results (30).
In our present study and some other previous studies
11,19), pioglitazone was initiated after PCI. In contrast,
ome investigators started pioglitazone before PCI (15,20).
t is unknown whether pre-treatment has some advantage
ver post-treatment strategy to prevent restenosis. Further
tudy is needed to compare pretreatment and post-
reatment strategies to prevent ISR in T2DM patients.
lso, it needs to be investigated how long pioglitazone
hould be continued to affect neointimal suppression.
Recently, pioglitazone has been reported to decrease the
ncidence of cardiovascular events in T2DM patients with a
revious history of MI (35,36). This favorable effect might
e explained by the antiatherosclerotic effect of this drug.
he CHICAGO (Carotid Intima-Media Thickness in
therosclerosis Using Pioglitazone) trial has demonstrated
hat pioglitazone treatment might suppress carotid intima-
edia thickness as compared with glimepiride (37). More
ecently, the PERISCOPE (Pioglitazone Effect on Regres-
ion of Intravascular Sonographic Coronary Obstruction
rospective Evaluation) trial has shown that pioglitazone
reatment dramatically suppresses coronary atherosclerosis
rogression as compared with glimepiride (30). In our
resent study, we did not find significant differences in serial
hanges of atherosclerotic plaque between the pioglitazone
nd control group. This discordant result might be due to
mall sample size. Our study is not powered to investigate
he impact of pioglitazone on untreated atherosclerotic
egments. However, our present study further addresses the
fficacy of pioglitazone on treated (stented) coronary vessel
all.
The impact of our results in the era of DES might be
ontroversial. Diabetes is still the strongest independent
linical predictor of ISR and stent thrombosis after DES
mplantation (4,38–41). Therefore, it is possible that TZDs
urther decrease ISR even after DES implantation. The
mpact of TZDs on neointimal proliferation after DES
mplantation should be investigated. Furthermore, recent
oncerns about the small but significant increased risk for
ery late stent thrombosis raised a question about unselected
r universal use of DES, and thus it is recommended that
ES should be used only for patients who tolerate extended
12 months) dual antiplatelet therapy (42–44). Pioglita-
one might be adjunctively used to decrease the chance of
SR in high-risk patients for ISR after BMS treatment in
he era of DES.
Several publications have suggested possible unfavorable
ffects of TZDs that increase incidence of MI and heart
ailure (45,46). A meta-analysis by Nissen and Wolski (45)
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530emonstrated that rosiglitazone treatment potentially in-
reased the incidence of MI, although another meta-
nalysis and report from a large-scale randomized trial did
ot conclude this unfavorable effect (47). However, a
arge-scale randomized study as well as a meta-analysis of
he randomized trials did not show increased risk of MI but
ather demonstrated decreased incidence of MI or death
fter pioglitazone treatment (35,48). In our present study, 2
ases were reported to have MI during follow-up, 1 in each
roup. One case in the pioglitazone group had an MI
ssociated with subacute stent thrombosis. Another case in
he control group had a periprocedural MI. Therefore, it is
nlikely that either is related to any anti-diabetic medica-
ions. It is well-known that TZDs increased small but
ignificant numbers of peripheral edema and congestive
eart failure (49). In our present study, despite a high-risk
linical profile, peripheral edema and congestive heart fail-
re did not statistically increase.
tudy limitations. Our study has some limitations. First,
lthough pioglitazone might be efficacious in some patients
ith T2DM, incidence of ISR is still higher than in those
atients who are treated with DES. Second, although a
avorable effect of pioglitazone on long-term clinical out-
ome has been reported by a large-scale randomized trial,
ur present study is not powered to address the long-term
rognostic impact of pioglitazone. Therefore, the longer-
erm clinical impact of pioglitazone will be required to
ddress this issue. Third, because our study has multiple end
oints without adjustment for multiplicity, the possibility of
ype 1 error could not be eliminated. Finally, use of TZDs
ight be limited by the increased incidence of peripheral
dema and heart failure. Although incidence of peripheral
dema or heart failure did not differ between patients
reated with and patients treated without pioglitazone in
his study, the long-term impact of pioglitazone on cardiac
unction and the incidence of heart failure should be
arefully monitored.
onclusions
ioglitazone suppresses in-stent neointimal proliferation
nd therefore reduces angiographical and clinical restenosis
months after PCI in patients with T2DM. The additive
mpact of pioglitazone on restenosis and TLR as well as
tent thrombosis after placement of DES needs further
nvestigations.
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